ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026
Design and mechanistic evaluation of chalcone-quinoline-triazole hybrids as antifungal CYP51 inhibitors.
Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A series of novel chalcone-quinoline-triazole hybrid compounds were rationally designed, synthesised, and evaluated for antifungal activity against clinically relevant Candida species, including C. albicans, C. glabrata, and C. krusei. Among the synthesized derivatives, compound 7b exhibited the most potent antifungal activity, with minimum inhibitory concentration (MIC) values ranging from 6.25 to 12.5 µM, surpassing the reference antifungal ketoconazole under identical experimental conditions. Time-kill kinetic studies further confirmed its concentration- and time-dependent fungicidal activity. Mechanistic investigations demonstrated that compound 7b markedly disrupted fungal sterol biosynthesis, as evidenced by significant ergosterol depletion, lanosterol accumulation, and a pronounced reduction in the ergosterol/lanosterol ratio across all tested Candida species. Concentration-response analysis of the normalised ergosterol/lanosterol ratio yielded low apparent IC₅₀ values for compound 7b, supporting potent inhibition of CYP51-dependent sterol conversion at the cellular level. Cytotoxicity assessment in mammalian cell lines (HepG2, HK2, and Vero) indicated that compound 7b possessed lower cytotoxicity and a more favourable selectivity profile than ketoconazole. Molecular docking studies revealed favourable binding interactions of compound 7b within the CYP51 active site, while 100 ns molecular dynamics simulations supplemented by MM-PBSA energy decomposition and hydrogen-bond occupancy analysis supported persistent non-covalent stabilisation of the ligand-protein complex. Collectively, the integration of synthetic chemistry, antifungal evaluation, cellular sterol profiling, and complementary computational modelling identifies compound 7b as a promising antifungal lead scaffold associated with disruption of CYP51-dependent ergosterol biosynthesis.
Indexed as
Identifiers
42599305What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.